U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX20462006: GSM7401381: DEC_rep4; Mus musculus; RNA-Seq
1 ILLUMINA (Illumina HiSeq 2500) run: 32.5M spots, 1.7G bases, 551.5Mb downloads

External Id: GSM7401381_r1
Submitted by: Integrative Genomics Core Lab, Shared Resources Department, City of Hope National Medical Center
Study: STAT3 inhibition permits epigenetic reprogramming and TLR9/IRF8-driven differentiation of inv(16) acute myeloid leukemia [RNASEQ_AML_DECSCR]
show Abstracthide Abstract
Cultured acute myeloid leukemia (AML) blasts can differentiate into antigen-presenting cells but achieving leukemic cell immunogenicity proved challenging in clinical setting. Despite expressing multiple immunostimulatory receptors, such as Toll-like Receptor 9 (TLR9), AML cells resist immunostimulation. We previously demonstrated that eliminating Signal Transducer and Activator of Transcription 1 and 3 (STAT1/3) signaling in AML cells using decoy DNA strategy (CpG-STAT3dODN) synergized with TLR9 stimulation and resulted in T cell-mediated leukemia regression. Here, we interrogated the molecular underpinnings of CpG-STAT3dODN-driven differentiation and immunogenicity of mouse Cbfb/MYH11/Mpl AML. The transcriptional profiling of AML cells isolated from mice after inducible Stat3 silencing plus TLR9 stimulation or CpG-STAT3dODN treatment, revealed comparable upregulation of genes related to myeloid cell differentiation (Irf8, Cebpa) and immune stimulation (Gadd45a, Ciita, Il12a, Ifng) but decreased expression of leukemia-promoting Runx1 and Run1t1. The conditional Irf8 silencing in AML cells almost completely abrogated TLR9-driven leukemia cell differentiation. The AML cell reprogramming by CpG-STAT3dODN was likely regulated epigenetically as revealed by reduced global promoter hypomethylation of crucial myeloid cell differentiation and immune activation genes. These changes were associated with reduced expression of known STAT3 targets, DNMT1 and DNMT3a/b. Finally, we provide initial evidence of anti-leukemic effects of CpG-STAT3 inhibitor against human AML model in humanized mice. Our studies suggest that, beyond oncogenic functions, STAT3 in AML cells may be a primary checkpoint in control of immune-stimulatory and differentiation driving effects. These findings support further development of CpG-STAT3 inhibitors as a new bi-functional agents for AML immunotherapy. Overall design: To unravel the molecular mechanism underlying leukemic cell differentiation in response to combined STAT3-inhibition/TLR9-stimulation, we compared global gene expression in sorted GFP+/c-Kit+CMM cells derived from spleens of mice treated three times every other dayin vivousing CpG-STAT3dODN, CpG-scrODN or PBS.
Sample: DEC_rep4
SAMN35301412 • SRS17774876 • All experiments • All runs
Organism: Mus musculus
Library:
Name: GSM7401381
Instrument: Illumina HiSeq 2500
Strategy: RNA-Seq
Source: TRANSCRIPTOMIC
Selection: cDNA
Layout: SINGLE
Construction protocol: Harvest spleen 1 day post last treatment and make single cell suspension, enrich c-Kit+ leukemia cells using STEMCELL EasySep™ PE Positive Selection Kit, extract RNA using Promega Maxwell RSC simplyRNA kit. RNA libraries for RNA-seq were prepared illumina RNA-seq Library Prep Kit following manufacturer's protocols.
Runs: 1 run, 32.5M spots, 1.7G bases, 551.5Mb
Run# of Spots# of BasesSizePublished
SRR2468257432,487,9451.7G551.5Mb2024-07-23

ID:
27885204

Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...